Nature Reviews Cancer

Papers
(The TQCC of Nature Reviews Cancer is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Linking pancreatic renewal and cancer initiation1581
Computing brain metastasis impact1125
Digging for treasures in the tumour interactome942
INVADEseq to study the intratumoural microbiota at host single-cell resolution578
An inhospitable site548
Combining spatial transcriptomics and AI to enhance brain tumour diagnosis517
Fructose takes a detour to feed cancer387
Emerging strategies to investigate the biology of early cancer364
Combinatorial strategies to target RAS-driven cancers364
Oncofetal reprogramming in tumour development and progression344
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment321
Artificial intelligence in cancer research, diagnosis and therapy313
Mapping the prostate cell family tree306
How medical anthropology can contribute to cancer research302
The evolution of cancer and ageing: a history of constraint302
Author Correction: Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma289
Connie J. Eaves (1944–2024)276
The recruitment of metastasis-associated monocytes261
Antihistamines boost immunotherapy257
Fighting cancer with fat244
Tertiary lymphoid structures as hubs of antitumour immunity243
Reply to ‘Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies’242
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies239
Translating premalignant biology to accelerate non-small-cell lung cancer interception224
Epithelial and stromal co-evolution and complicity in pancreatic cancer220
Context-dependent functions of pattern recognition receptors in cancer213
Targeting transcription cycles in cancer202
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel191
3D chromatin architecture as a predictor of somatic mutations in cancer genomes190
No mutation, tumour initiation185
Impersonating neurons183
Under pressure179
Nanoreceptors take down mutant p53178
Gut microbes produce novel genotoxic metabolites173
Tumour EVPs disrupt liver function171
Dendritic cells rise and shine170
Removing barriers to address sex differences in anticancer drug toxicity168
Persistence is key168
Thelpers? More like Ttroublemakers166
AACR 2025161
Measuring HLA disruption using MHC Hammer158
Moonlighting functions of glucose metabolic enzymes and metabolites in cancer155
Defining a ‘cells to society’ research framework for appendiceal tumours151
Remodelling of the tumour microenvironment by the kallikrein-related peptidases145
Natural killer cells in antitumour adoptive cell immunotherapy143
3D bioprinted cancer models: from basic biology to drug development142
How chemokines organize the tumour microenvironment137
B-ring sterols to the rescue127
Points of entry for tumour-infiltrating lymphocytes127
Bone voyage: immune crosstalk sets sail123
Identifying spatial cellular structures with SPACE-GM122
In-depth organoid profiling of pancreatic cancer117
Visualizing intratumoural heterogeneity with EpicMIBI115
Environmental endocrine disruptors: rethinking the origins of early-onset ER+ breast cancer114
Un-Fair Skin: racial disparities in acral melanoma research112
Leveraging the replication stress response to optimize cancer therapy108
The path to leptomeningeal metastasis108
Metabolic interplays between the tumour and the host shape the tumour macroenvironment107
Linking cell mechanical memory and cancer metastasis107
Dynamics and specificities of T cells in cancer immunotherapy103
Regulatory T cells in the tumour microenvironment103
In situ decellularization of tissues to resolve the tumour-associated matrix102
Race influences the tumour microbiome97
Understanding and addressing race disparities in childhood cancer outcomes97
Taming TAMs in brain metastases97
Encoding spatial tumour dynamics with Starfysh97
Deciphering the cancer genome and epigenome96
Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic95
The link between vitamin D and prostate cancer95
Polygenic scores in cancer94
Targeted protein degradation for cancer therapy92
Acetyl-CoA metabolism in cancer88
Cancer nanomedicine86
RNA splicing dysregulation and the hallmarks of cancer84
Z-nucleic acids give immunotherapy a boost82
Author Correction: Antibody-based proteomics: fast-tracking molecular diagnostics in oncology80
Local CAR manufacturing80
Parity modulates epithelial–immune cell communication76
Right ON target: a new RAS-GTP inhibitor74
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities72
Defining precancer: a grand challenge for the cancer community71
Integrative medicine in oncology: redefining the standard of care69
A trojan horse to target spliceosome mutant cells68
Prime editing GEMMs to model cancer mutations67
NOTUM-mediated stem cell competition in CRC67
Expanding the utility of precision oncology knowledge bases65
Chromothripsis in cancer61
Tertiary lymphoid structures in anticancer immunity60
Targeting ferroptosis as a vulnerability in cancer59
Starting a new job56
Quantum probes in cancer research55
Functional lineage tracing to study the clonal evolution of therapy resistance54
In vivo labelling system to study cell neighbourhoods50
Revealing genomic secrets of archival FFPE samples49
Judith Campisi (1948–2024)48
New pathogen on the block48
Glycogen condensates drive tumorigenesis by trapping Hippo kinases46
The present and future of the Cancer Dependency Map45
Recent advances in therapeutic cancer vaccines45
Neutrophils: a roadblock for immunotherapy45
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart44
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data42
Inferring cancer metabolism from gene-expression data42
Carcinogenesis at single-cell resolution39
Cell states can give tumorigenesis a head start38
Bidirectional CART.BiTE cells bring new hope35
Patient-derived organoids unveil sarcoma vulnerabilities34
Global post-mortem tissue donation programmes to accelerate cancer research34
Epigenomic heterogeneity as a source of tumour evolution32
Evolution and progression of Barrett’s oesophagus to oesophageal cancer32
Transfer RNAs as dynamic and critical regulators of cancer progression32
Developing dietary interventions as therapy for cancer30
A timeline of tumour-associated macrophage biology30
Traject3d for studying 3D cellular heterogeneity29
Harnessing the influenza virus to fight cancer28
Author Correction: Integrative medicine in oncology: redefining the standard of care28
Digitally enhanced Raman spectroscopy28
Neuro-immune cross-talk in cancer27
0.14353799819946